Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024

On July 23, 2024 Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, reported financial results for the second quarter ended June 30, 2024 (Press release, Quest Diagnostics, JUL 23, 2024, View Source [SID1234645016]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We delivered another strong quarter, with base business revenue growth of nearly 4% and total revenue growth of 2.5% as well as continued improvement in productivity and profitability in the base business," said Jim Davis, Chairman, CEO and President. "This performance is due to growth of new physician and hospital customers, more favorable test mix that includes greater adoption of advanced diagnostics and continued strength in healthcare utilization. We also made progress improving our operational quality and efficiency through greater use of automation and AI."

Mr. Davis added: "In addition, we are excited to announce four acquisitions that meet our criteria for growth, profitability and returns, and that will enable us to expand in strategic growth areas. Our planned acquisition of LifeLabs will position us to help this trusted lab leader grow and better serve Canada’s growing and aging population. The acquisitions we recently announced of select outreach lab assets of Allina Health in Minnesota and Wisconsin and OhioHealth in Ohio reflect our ability to partner with high-quality health systems and extend our presence in key geographies. Our recently completed PathAI Diagnostics acquisition positions us to rapidly scale digital pathology innovation to help health systems and other providers improve cancer diagnoses."

Three Months Ended June 30,

Six Months Ended June 30,

2024

2023

Change

2024

2023

Change

(dollars in millions, except per share data)

Reported:

Net revenues

$ 2,397

$ 2,338

2.5 %

$ 4,763

$ 4,669

2.0 %

Diagnostic Information Services revenues

$ 2,333

$ 2,268

2.8 %

$ 4,631

$ 4,527

2.3 %

Revenue per requisition

1.6 %

0.9 %

Requisition volume

1.1 %

1.4 %

Organic requisition volume

0.7 %

0.9 %

Operating income (a)

$ 355

$ 348

1.9 %

$ 655

$ 653

0.2 %

Operating income as a percentage of net revenues (a)

14.8 %

14.9 %

(0.1) %

13.7 %

14.0 %

(0.3) %

Net income attributable to Quest Diagnostics (a)

$ 229

$ 235

(2.4) %

$ 423

$ 437

(3.1) %

Diluted EPS (a)

$ 2.03

$ 2.05

(1.0) %

$ 3.75

$ 3.83

(2.1) %

Cash provided by operations

$ 360

$ 444

(18.9) %

$ 514

$ 538

(4.4) %

Capital expenditures

$ 92

$ 104

(10.8) %

$ 196

$ 231

(14.9) %

Adjusted (a):

Operating income

$ 398

$ 389

2.1 %

$ 747

$ 739

1.0 %

Operating income as a percentage of net revenues

16.6 %

16.7 %

(0.1) %

15.7 %

15.8 %

(0.1) %

Net income attributable to Quest Diagnostics

$ 266

$ 263

1.4 %

$ 496

$ 495

0.2 %

Diluted EPS

$ 2.35

$ 2.30

2.2 %

$ 4.39

$ 4.34

1.2 %

(a)

For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below.

Updated Guidance for Full Year 2024

The company updates its full year 2024 guidance as follows:

Updated Guidance

Prior Guidance

Low

High

Low

High

Net revenues

$9.50 billion

$9.58 billion

$9.40 billion

$9.48 billion

Net revenues increase

2.7 %

3.5 %

1.6 %

2.5 %

Reported diluted EPS

$7.57

$7.77

$7.57

$7.82

Adjusted diluted EPS

$8.80

$9.00

$8.72

$8.97

Cash provided by operations

Approximately $1.3 billion

Approximately $1.3 billion

Capital expenditures

Approximately $420 million

Approximately $420 million

The company’s updated guidance does not include the impact of the pending LifeLabs acquisition given the uncertainty around when the transaction will close. The company continues to expect to complete the transaction by the end of the year, subject to certain customary closing conditions and approvals, including Canadian regulatory approvals.

Note on Non-GAAP Financial Measures

As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments, and other items.

Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.

Conference Call Information

Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at www.QuestDiagnostics.com/investor. We suggest participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on July 23, 2024 until midnight Eastern Time on August 6, 2024, by phone at 866-363-1805 for domestic callers or 203-369-0193 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.